Dual renin-angiotensin system blockade in heart failure.

[1]  F. Messerli.  The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. , 2009, Journal of the American College of Cardiology.

[2]  D. Atar,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ , 2008, European journal of heart failure.

[3]  Akshay S. Desai,et al.  Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. , 2007, Journal of the American College of Cardiology.

[4]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[5]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[6]  J. McMurray,et al.  Treatment of chronic heart failure: a comparison between the major guidelines. , 2006, European heart journal.

[7]  J. Cohn,et al.  Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val‐HeFT , 2004, European journal of heart failure.

[8]  S. Yusuf,et al.  Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. , 2003, European heart journal.

[9]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[10]  N. Hollenberg,et al.  Literature alert , 2002 .